Abuse liability preclinical

Kalman D (2002) The subjective effects of nicotine methodological issues, a review of experimental studies, and recommendations for future research. Nicotine Tob Res 4 25-70 Katz JL, Goldberg SR (1988) Preclinical assessment of abuse liability of drugs. Agents Actions 23 18-26... 

Substance abuse is defined by maladaptive patterns of drug-taking behavior that produce symptoms to indicate that the individual continues use of the substance despite significant substance-related problems [9], The goal of preclinical abuse liability evaluations is to predict the likelihood that some drug will maintain these maladaptive patterns of drug-taking behavior in a... 

Series of articles on pharmacology, kinetics, clinical studies J. CUn. Pharmacol 20, 213-424 (1980). Preclinical narcotic abuse liability evaluation J. H Woods et al, Arz-neimittei-Forsch. 33, 218 (1983). Multicenter clinical study in painful conditions C E. Steele, W, L, Jefferson, Curr. Med. Res. Opin. 8, 382 (1983). Review of pharmacology and therapeutic efficacy P. A. Morley er al. Drugs 23, 250-275 (1982). Comprehensive description M, Zinic et at in Analytical Profiles of Drug Substances vol. 15, K. Florey, Ed. (Academic Press, New York, 1986) pp 673-698,... 

In addition, kinetics need to be determined in the preclinical abuse liability studies. A CNS-active drug candidate with a kinetic profile demonstrating a short half-life might be subject to potential abuse. 

Conclusion To date no in vitro models are available to study the physical dependence potential and the rewarding and reinforcing properties of novel CNS-active drug candidates in development. The preclinical abuse liability assessment represents the integrated data of in vivo animal studies to predict the abuse potential of CNS-active drug candidates. 

What Is the Future in Preclinical Abuse Liability Testing . 129... 

In the last 15 years, there has been a renewed interest by the pharmaceutical industry for the conduct of preclinical abuse liability assessments. The timeline of regulatory events from the Food and Dmg Administration (FDA) and European Medicines Agency (EMA) has motivated the increased industry interests (see Fig. 1 for an illustration of the relationship between significant events affecting the... 

The preclinical data can also impact the design and breadth of the clinical abuse liability package that will be expected. In addition, the data from the dependence... 

---